GLAUKOS Corp (GKOS): Results of Operations and Financial Condition
GLAUKOS Corp (GKOS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 gkos-ex99_2.htm EX-99.2 EX-99.2 Exhibit 99.2 JULY 29, 2026 GLAUKOS CORPORATION (NYSE: GKOS) SECOND QUARTER 2026 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designe
How this was made
The 30-second read
Why it matters
Traders can update models using the reported 2Q revenue performance and the explicit FY2026 consolidated revenue guidance range, plus product-level adoption signals (iDose TR and Epioxa).
Market read
A primary-source quarterly update with a defined FY2026 revenue range is actionable for positioning around earnings expectations and guidance credibility.
What to watch
The excerpt emphasizes non-GAAP gross margin and guidance but does not include detailed expense trajectory, R&D/commercial spend changes, or segment profitability, which can affect valuation despite top-line strength.
Background
This SEC 8-K (Item 2.02) is Glaukos’ quarterly results review ahead of its scheduled conference call.
Ticker impact
Glaukos reports 2Q 2026 net revenues of $185.6M (+50% YoY) and FY2026 sales guidance of $680M to $700M.
Likely positive bias for GKOS as the filing shows strong growth and raises confidence via a defined FY2026 guidance range.
This is a primary-source earnings-style update (8-K Item 2.02) with concrete revenue growth, gross margin, cash balance, and a specific full-year guidance band.
Market effects
Reinforces demand read-through for ophthalmic interventional glaucoma and corneal cross-linking platforms, potentially supporting sentiment across specialty eye-care peers.
U.S. growth is the main driver (iDose TR sales), while international expansion remains an additional contributor.
Guidance and adoption commentary may influence broader investor appetite for ophthalmic med-tech commercialization stories globally.
Counterpoint
Revenue growth may be heavily dependent on iDose TR adoption and early Epioxa contributions, so any payer access delays could cap upside.
Key entities
- companyGLAUKOS CORPORATION
Ophthalmic pharmaceutical and medical technology company reporting 2Q 2026 results and FY2026 revenue guidance.
- productiDose TR
Intracameral procedural pharmaceutical for glaucoma therapy; cited as driving U.S. growth and adoption.
- productEpioxa
Epithelium-on corneal cross-linking therapy for keratoconus; cited with initial commercial launch progress and sales.
